Tirzepatide
The Dual-Hormone Peptide Behind Mounjaro and Zepbound
Tirzepatide is an engineered peptide that acts on two of the body's gut-hormone systems at once, GLP-1 and GIP, where most weight and diabetes medicines act on only one. As the molecule inside Mounjaro and Zepbound, it steadies blood sugar and quiets appetite, and in head-to-head research it has pulled ahead of its single-hormone cousin.
It is the GLP-1 peptide we reach for most in our practice today. We use it deliberately: a low starting amount, a slow climb, close follow-up, and a clear plan for coming off once the weight is gone.
.svg)
What we have seen in practice
Our GLP-1 work started with semaglutide years ago. Tirzepatide arrived later and has gradually become the one we prescribe most: its two-receptor design and the head-to-head trial results both back that choice. Semaglutide still suits some patients better, and we keep both in the toolkit.
How we dose it is most of the story. The field's early instinct was to push these medicines hard, and pushing hard is what created the horror stories: weight coming off so fast that faces hollowed, muscle disappeared with the fat, and hair thinned. We took the opposite lesson. Dr. Koniver starts low, raises the amount slowly if at all, and does not rush, with a working ceiling of about two pounds of loss a week. At that pace, with regular check-ins, people keep their muscle, their hair, and their energy while the weight comes off. The few who respond strongly and lose faster than expected are exactly why the follow-up stays close.
Dr. Koniver sees the medicine's real job as getting someone to their weight, then handing the work back to habits they now own. For patients tapering off tirzepatide, or building a foundation before starting, we often turn to a growth-hormone-peptide combination. It cannot match tirzepatide for raw effect, but alongside clean eating, daily walking, and good sleep it gives real support to lean muscle and fat burning.
Tirzepatide at a glance
An engineered 39-amino-acid peptide that activates two gut-hormone receptors, GLP-1 and GIP, built by Eli Lilly to last about a week in the body [6]
.svg)
Blood sugar control in type 2 diabetes, medically supervised weight loss, and obstructive sleep apnea in adults with obesity
.svg)
Among the deepest in this directory: multiple large randomized trials, including a head-to-head win over semaglutide and a heart-failure outcomes trial [1, 2, 5]
.svg)
A once-weekly injection under the skin
.svg)
39 amino acids, formula C225H348N48O68, about 4,813 g/mol, half-life about five days [6]
An approved prescription medicine in the US and worldwide under the Mounjaro and Zepbound names; compounded copies were wound down in 2025; not prohibited in sport. Details below
The GLP-1 we now reach for most, used with discipline: low and slow, muscle protected, with a planned off-ramp. See what we have seen in practice above
39 residues built on the GIP backbone. Pink beads = the two Aib substitutions (positions 2 and 13) that resist the enzyme which clears these hormones within minutes. Green bead = the lysine carrying the fatty-acid chain that anchors the peptide to albumin.
Where tirzepatide comes from
Your gut already runs the system tirzepatide borrows. After a meal, the intestine releases incretin hormones, GLP-1 and GIP among them, that tell the pancreas to release insulin, calm the liver's sugar output, slow the stomach, and signal fullness to the brain. GLP-1 became the first blockbuster target for that biology. Tirzepatide's insight was to work both incretin receptors at once rather than just one.
To turn that idea into a once-weekly medicine, scientists started from the GIP hormone's structure and reworked it so a single molecule could switch on both receptors, then added the same durability tricks used across this class: substitutions that resist the enzyme that clears these hormones within minutes, and a fatty-acid tail that keeps the peptide riding through the bloodstream bound to albumin. The result became Mounjaro for diabetes in 2022 and Zepbound for weight management in 2023, and it quickly became one of the most talked-about medicines in the world.
Last minutes
Resists breakdown, binds albumin
Lasts about a week
How it works
Tirzepatide activates two incretin receptors, and the combination is the point.
It prompts insulin release when blood sugar is high, quiets the liver's sugar output, slows the stomach so meals last longer, and reaches appetite centers so portions shrink. This is the mechanism Dr. Koniver points to first: fuller sooner, satisfied longer, eating less without feeling deprived. Ref [1, 3]
.svg)
Switching on the GIP receptor contributes further insulin release with preserved pancreatic function and improves how muscle and fat handle glucose. Working both receptors together is the leading explanation for why tirzepatide tends to produce a larger average effect. Ref [1]
.svg)
Across blood sugar and appetite, the two-receptor action pushes metabolism in the same direction from several angles at once, which is what the head-to-head research reflects. Ref [1, 2]
The head-to-head result, about 20% versus about 14% for semaglutide, is the plain reason we reach for tirzepatide first [2]
What the research shows
This is one of the rare directory pages where the human evidence is the strong suit, and we can simply report it.
In the pivotal obesity trial, SURMOUNT-1, 2,539 adults with obesity received weekly tirzepatide or placebo for 72 weeks alongside lifestyle support. Average weight loss reached about 15% at the lowest dose and roughly 21% at the highest, against about 3% with placebo, and the large majority lost at least 5% of their weight. The comparison that matters most for how we practice came later: in SURMOUNT-5, a head-to-head trial against semaglutide, tirzepatide produced about 20% weight loss versus about 14%, and came out ahead at every threshold. That result is the plain reason we now reach for tirzepatide first.
The evidence runs past weight, too. In type 2 diabetes, tirzepatide outperformed semaglutide on blood sugar and weight in a direct comparison. In obstructive sleep apnea, it cut the number of breathing interruptions per hour enough to earn the first FDA approval any drug has received for that condition. And in a heart-failure trial in people with the preserved-ejection-fraction form of the disease and obesity, tirzepatide reduced the combination of cardiovascular death and worsening heart failure by nearly 40% over about two years. We report that last one as promising trial evidence, not as an approved heart-failure use.
SURMOUNT-1, 2022 [1]
2,539 adults with obesity
Placebo-controlled, double-blind, randomized, 72 weeks
About 15% to 21% weight loss across doses vs about 3% placebo
Trial conditions; 72 weeks
SURMOUNT-5, 2025 [2]
751 adults with obesity
Head-to-head vs semaglutide, randomized, 72 weeks
About 20% weight loss vs about 14% for semaglutide
Two-drug comparison, not placebo
SURMOUNT-OSA, 2024 [4]
Adults with obesity and sleep apnea
Randomized, placebo-controlled
Large drop in breathing interruptions; basis for the OSA approval
Specific population
SUMMIT, 2025 [5]
731 adults with HFpEF and obesity
Randomized, placebo-controlled outcomes trial
Nearly 40% fewer cardiovascular-death or worsening-heart-failure events
Not yet an approved heart-failure use
How strong is the evidence
Among the strongest evidence bases in this directory - with an honest row for the heart-failure use that is promising but not yet approved.
Because so many people have taken tirzepatide in trials, its risks are unusually well charted. The everyday effects are digestive, nausea most of all early on, plus diarrhea, constipation, or vomiting, and they tend to fade as the body settles in. Dr. Koniver is upfront that these exist, and they are precisely why the practice climbs the dose slowly: rush the titration and you buy yourself most of the discomfort people dread.
The uncommon risks are the ones to know by name. A boxed warning sits on the US label because rodents developed thyroid C-cell tumors; whether that carries over to people is not known either way, but a history, personal or in the family, of medullary thyroid cancer or MEN 2 rules the drug out. Pancreatitis, gallbladder trouble (more likely when weight drops fast), and a rare gut-motility problem called ileus are all on the label. NAION, a rare optic-nerve condition, has surfaced as a question across this drug class and is being tracked. Fast weight loss can also cost muscle, no small thing past midlife, which is the reason behind our deliberate pace and emphasis on protein. Tirzepatide is not used in pregnancy or breastfeeding.
The 2025 market shift changed the sourcing picture: now that compounded copies have been wound down, anything sold outside a licensed pharmacy is a real risk. Get this medicine from a licensed pharmacy against a genuine prescription, and nowhere else.
Regulatory status
Regulatory information current as of 13 August 2026. This is a summary, not legal or medical advice, and status can change.
Mounjaro - approved for type 2 diabetes
Zepbound - approved for chronic weight management
Zepbound for sleep apnea: the first drug ever approved for OSA
Heart-failure trial (SUMMIT): strong HFpEF data - not yet an approved use
United States - APPROVED
An approved prescription medicine as Mounjaro (type 2 diabetes) and Zepbound (weight management and obstructive sleep apnea). A large 2025 trial showed benefit in a form of heart failure, though that is not yet an approved use.
Compounded copies
WOUND DOWN
Permitted during the shortage, then stopped in March 2025 (compounding pharmacies, then outsourcing facilities). In April 2026 the FDA moved to close the remaining bulk-compounding pathway. Narrow medical-need exceptions only.
Sport (WADA)
MONITORED
· NOT PROHIBITED
Not prohibited. Added to the World Anti-Doping Agency's monitoring program at the start of 2026, so use by athletes is tracked but not banned. Competing athletes should keep an eye on future lists.
Everywhere else - REGULATED MEDICINE
Prescribing specifics vary by country, but tirzepatide is a regulated medicine almost wherever it is sold; anything outside licensed channels carries the quality risks in the safety section.
Regulatory information current as of 13 August 2026. Design note: green approvals plus neutral cards, no red anywhere - the same treatment as the Semaglutide page. Verify the heart-failure indication status at publication.
Common questions
Yes. It is a 39-amino-acid peptide, engineered to act on two gut-hormone receptors at once. As Dr. Koniver puts it, the GLP-1 medicines are peptides; tirzepatide is simply the one that works two receptors instead of one.
They contain the same molecule. Mounjaro is approved for type 2 diabetes, and Zepbound is approved for weight management and for obstructive sleep apnea. The regulatory section above lays out which product carries which approval.
Semaglutide activates the GLP-1 receptor; tirzepatide activates GLP-1 plus a second gut-hormone receptor, GIP. In a head-to-head trial, tirzepatide produced more weight loss. In our practice we now use tirzepatide most, with semaglutide remaining the right choice for some patients; the deciding factors are individual response and tolerance.
Without a plan, it tends to: this whole class works while it is taken, and stopping without new habits usually gives ground back. That is why our approach treats tirzepatide as a tool with an exit, with habits built during the loss and, for many patients, a peptide-supported off-ramp rather than an abrupt stop.
For the most part, no. The 2025 rule changes closed out the compounded-copy era; the regulatory status section above walks through exactly what changed and when.
Related in this directory
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID 35658024.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. PMID 40353578.
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PMID 34170647.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205. PMID 38912654.
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). N Engl J Med. 2025;392(5):427-437. PMID 39555826.
- Molecular data: tirzepatide, PubChem CID 166567236, formula C225H348N48O68, molecular weight ~4,813 g/mol, 39 amino acids with two Aib residues and a C20 fatty-diacid side chain. Regulatory sources: FDA (approvals through December 2024 and compounding actions through April 2026), WADA 2026 Monitoring Program.
This page is for informational and educational purposes and does not constitute medical advice, diagnosis, or treatment. Tirzepatide is a prescription medicine; whether it is appropriate for any individual is a decision for that person and their licensed clinician. Statements describing how Dr. Koniver and the Koniver Wellness team use GLP-1 medicines reflect clinical experience and judgment, which is not the same as controlled clinical evidence. Nothing here is a substitute for consultation with a qualified healthcare provider. Weight-management care at Koniver Wellness is provided under physician supervision after appropriate screening. Regulatory information on this page is provided for general awareness, is current as of the date shown, and may have changed; verify with official sources or a licensed practitioner in your jurisdiction before making any decision.
INTERESTED IN PEPTIDES?
START WITH THE RIGHT QUESTIONS.
Understand what peptides can and cannot do, what the evidence actually says, and whether physician-guided peptide therapy makes sense for you.